510(k) K162827
K162827 is an FDA 510(k) premarket notification submitted by bioMerieux, Inc. for the device "VIDAS B.R.A.H.M.S. PCT (PCT)". The FDA issued a decision of Substantially Equivalent on February 23, 2017. The device falls under product code PRI (Procalcitonin Assay), a Class II device regulated under 21 CFR 866.3215. bioMerieux, Inc. has at least 10 other 510(k) clearances on record.
Clearance Details
- Decision
- SESE (Substantially Equivalent)
- Decision Date
- February 23, 2017
- Date Received
- October 7, 2016
- Clearance Type
- Traditional
- Expedited Review
- No
- Third Party Review
- No
Device Classification
- Device Name
- Procalcitonin Assay
- Device Class
- Class II
- Regulation Number
- 866.3215
- Review Panel
- MI
- Submission Type
To aid in decision making on antibiotic therapy, including antibiotic initiation and discontinuation, for inpatients or patients in the Emergency Department, with suspected or confirmed lower respiratory tract infections (LRTI) defined as community-acquired pneumonia (CAP), acute bronchitis, and acute exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD).